NIIMBL eXperience Program Announces 17 Students for 2021 Cohort
News provided by
Share this article
Share this article
NEWARK, Del., April 20, 2021 /PRNewswire/ The National Institute for Manufacturing Biopharmaceuticals (NIIMBL) announced 17 students selected for their 2021 NIIMBL eXperience Program. The NIIMBL eXperience is offered to African American/Black, Latinx, and Native American college freshman and sophomores students from Historically Black Colleges and Universities (HBCUs) and NIIMBL member institutions and provides real-world insight into career options in the growing biopharmaceutical industry. This year we are happy to welcome a group of students from schools ranging from Morehouse College to MIT. Each cohort is extremely unique. The students come from different backgrounds and majors, however being able to inform them of the endless opportunities in the biopharmaceutical industry significantly broadens their scope of possibilities for their field of study,
NIIMBL eXperience Program Announces 17 Students for 2021 Cohort
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEWARK, Del., April 13, 2021 /PRNewswire/ The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce that Dr. Gene Schaefer has joined the Institute as NIIMBL Senior Fellow, effective April 5, 2021. Dr. Schaefer joins NIIMBL with over 35 years of experience in the biopharmaceutical field ranging from early stage process development to commercial product support for protein therapeutics.
Dr. Gene Schaefer has joined NIIMBL as Senior Fellow.
Prior to joining NIIMBL, Dr. Schaefer was Senior Director, API Large Molecule Pharmaceutical Development & Manufacturing Sciences at Johnson & Johnson. He also led the Protein Therapeutics Development group at Bristol-Myers Squibb with additional industry experience with Schering-Plough and Genzyme.
Delaware Business Now
Reading Time: 3 minutes
The CEO of Amtrak and both of Delaware’s U.S. Senators offered praise for the Biden-Harris administration’s $2 trillion-plus infrastructure bill known as the American Jobs Plan.
U.S. Sen. Chris Coons’ office listed the following proposed infrastructure programs.
A bill introduced by Sens. Coons and Bill Cassidy (R-La.) will help develop carbon capture and storage (CCS) infrastructure to reduce emissions of CO2 – or carbon dioxide, a greenhouse gas, while creating regional economic opportunities and jobs.
$80 billion for Amtrak over eight years. Last week, Sens. Coons and Chris Murphy (D-Conn.) led a group of 12 other senators from states along the Northeast Corridor (NEC) in aletter urging President Biden to support $55 billion in long-term funding for passenger rail infrastructure to repair the NEC rail network. The letter also called for robust support to expand the Amtrak passenger rail service nationwide.
FDA Steps Up Support For Advanced Manufacturing Technologies
The latest article by FDA Commissioner Hahn
1 is one of a string of communications and guidances emphasizing the agency’s support for the adoption of advanced manufacturing technologies (AMTs) and processes. The FDA has defined advanced manufacturing as new and emerging approaches for the production of medical technologies that can improve drug quality, address shortages of medicines, and speed time-to-market. The agency recognizes that AMT subsumes a broad swath of production techniques, including:
The integration of novel technology approaches;
The use of established techniques in a new or innovative way;
Applying production methods in a new domain where there are no defined best practices or experiences.
vimarsana © 2020. All Rights Reserved.